Investigational drug · Phase 3
SHR0302
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non-segmental Vitiligo, Psoriatic Arthritis.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
32
Any phase or sponsor naming "SHR0302"
First trial start
2021
Aug 30, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SHR0302", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-segmental Vitiligo
- Psoriatic Arthritis
Approved drugs for the same conditions: Psoriatic arthritis · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "SHR0302" as an intervention, largest first.
- Evaluate the Efficacy and Safety of Topical SHR0302 Ointment in Patients With Mild-to-Moderate Atopic DermatitisPivotal-lookingStatus unknown
Reistone Biopharma Company LimitedIndustry
NCT04717310 · 645 participants · Start Dec 30, 2020 · Primary completion Sep 8, 2023
Drug: SHR0302 Ointment; SHR0302 Ointment and 2 more · For: Atopic Dermatitis
Sites: Hefei, China; Beijing, China; Chongqing, China · 31 sites in all
- A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Rheumatoid ArthritisPivotal-lookingCompleted
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT04333771 · 566 participants · Start Jul 31, 2020 · Primary completion Jan 30, 2023
Drug: SHR0302; Placebo · For: Rheumatoid Arthritis
Sites: Liuzhou, China
- A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Ankylosing SpondylitisPivotal-lookingCompleted
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT04481139 · 504 participants · Start Oct 14, 2020 · Primary completion Nov 15, 2022
Drug: SHR0302; SHR0302 placebo · For: Ankylosing Spondylitis
Sites: Beijing, China
- To Evaluate the Efficacy and Safety of SHR0302 Tablet in Subjects of Active Psoriatic ArthritisPivotal-lookingActive, not recruiting
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT04957550 · 418 participants · Start Aug 30, 2021 · Primary completion Dec 13, 2026
Drug: SHR0302 tablets、Placebo; SHR0302 tablets、Placebo and 1 more · For: Psoriatic Arthritis
Sites: Beijing, China
- A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative ColitisPivotal-lookingStatus unknown
Reistone Biopharma Company LimitedIndustry
NCT05181137 · 368 participants (planned) · Start Nov 5, 2021 · Primary completion Oct 31, 2024
Drug: SHR0302; Placebo · For: Ulcerative Colitis
Sites: Dothan, Alabama; Lancaster, California; New Haven, Connecticut · 113 sites in all
- Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older With Moderate to Severe Atopic DermatitisPivotal-lookingCompleted
Reistone Biopharma Company LimitedIndustry
NCT04875169 · 336 participants · Start Apr 30, 2021 · Primary completion Aug 12, 2022
Drug: Core Treatment Active Experimental: SHR0302 Dose#1; Core Treatment Active Experimental: SHR0302 Dose#2 and 3 more · For: Atopic Dermatitis
Sites: Calgary, Canada; Surrey, Canada; Winnipeg, Canada · 52 sites in all
- Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia AreataPivotal-lookingStatus unknown
Reistone Biopharma Company LimitedIndustry
NCT05470413 · 330 participants · Start Apr 18, 2022 · Primary completion Oct 31, 2023
Drug: SHR0302; SHR0302 and 1 more · For: Alopecia Areata
Sites: Hefei, China; Beijing, China; Chongqing, China · 31 sites in all
- A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Non-Radiographic Axial SpondyloarthritisPivotal-lookingStatus unknown
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT05324631 · 300 participants (planned) · Start Aug 16, 2022 · Primary completion Aug 30, 2024
Drug: SHR0302; SHR0302 placebo · For: Non-radiographic Axial Spondyloarthritis
Sites: Beijing, China
- Study of SHR0302 Tablets (SHR0302) as Monotherapy in Active Rheumatoid Arthritis (RA) PatientsPivotal-lookingCompleted
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT03254966 · 194 participants · Start Nov 24, 2017 · Primary completion Apr 16, 2019
Drug: SHR0302; Placebo · For: Rheumatoid Arthritis
Sites: Beijing, China
- A Trial of SHR0302 Tablets and SHR0302 Base Gel in Patients With Non-segmental VitiligoPivotal-lookingRecruiting
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT07251595 · 176 participants (planned) · Start Dec 5, 2025 · Primary completion Mar 2027
Drug: SHR0302 Tablets; SHR0302 Base Gel and 2 more · For: Non-segmental Vitiligo
Sites: Jinan, China
Newest research
PubMed records naming it or its code names, newest first.
- Early response to ivarmacitinib and its impact on long-term efficacy in patients with moderate-to-severe atopic dermatitis: a post hoc analysis of a phase-III trial.
Chen J, Hu F, Zhang P, et al. · J Dermatolog Treat 2026
- Ivarmacitinib in patients with moderate to severe atopic dermatitis stratified by baseline characteristics: a post-hoc analysis of a phase 3 clinical trial.
Gu C, Chen A, Yin H, et al. · J Dermatolog Treat 2026
- Mechanistic study on the species differences in metabolism and excretion pathways of ivarmacitinib between humans and rats.
Huang X, Zhuang D, Zheng Y, et al. · Drug Metab Dispos 2026
- Pharmacokinetics and safety of SHR0302, a selective JAK1 inhibitor, in Chinese patients with hepatic impairment.
Mai J, Lin H, Wu M, et al. · Front Pharmacol 2026
- Effect of ivarmacitinib on patient-reported outcomes in patients with moderate-to-severe active rheumatoid arthritis: a post-hoc analysis of a phase III trial.
Xia N, Zhu L, Zhang W, et al. · Clin Rheumatol 2026
- Effect of ivarmacitinib on swelling and tenderness in small and large joints and imaging changes in patients with moderate-to-severe RA: a post hoc analysis of a phase III clinical trial.
Han Y, Ding M, Cui S, et al. · Naunyn Schmiedebergs Arch Pharmacol 2026
Also in development for Non-segmental Vitiligo
- VC005Phase 35 trials
Jiangsu vcare pharmaceutical technology co., LTD · Non-segmental Vitiligo, Non-Segmental Vitiligo, Atopic Dermatitis
- GIA632Phase 23 trials
Novartis · Atopic Dermatitis, Non-segmental Vitiligo, Cutaneous Lichen Planus
- SHR0302BasePhase 22 trials
Jiangsu HengRui Medicine Co., Ltd. · Vitiligo, Non-segmental Vitiligo
- ACT-777991Phase 21 trial
Idorsia Pharmaceuticals Ltd. · Non-Segmental Vitiligo
- EI-001Phase 21 trial
Elixiron Immunotherapeutics (Hong Kong) Ltd. · Non-segmental Vitiligo
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.